Application of transfer learning for cancer drug sensitivity prediction

Saugato Rahman Dhruba, Raziur Rahman, Kevin Matlock, Souparno Ghosh, Ranadip Pal

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: In precision medicine, scarcity of suitable biological data often hinders the design of an appropriate predictive model. In this regard, large scale pharmacogenomics studies, like CCLE and GDSC hold the promise to mitigate the issue. However, one cannot directly employ data from multiple sources together due to the existing distribution shift in data. One way to solve this problem is to utilize the transfer learning methodologies tailored to fit in this specific context. Results: In this paper, we present two novel approaches for incorporating information from a secondary database for improving the prediction in a target database. The first approach is based on latent variable cost optimization and the second approach considers polynomial mapping between the two databases. Utilizing CCLE and GDSC databases, we illustrate that the proposed approaches accomplish a better prediction of drug sensitivities for different scenarios as compared to the existing approaches. Conclusion: We have compared the performance of the proposed predictive models with database-specific individual models as well as existing transfer learning approaches. We note that our proposed approaches exhibit superior performance compared to the abovementioned alternative techniques for predicting sensitivity for different anti-cancer compounds, particularly the nonlinear mapping model shows the best overall performance.

Original languageEnglish
Article number497
Pages (from-to)497
JournalBMC Bioinformatics
Volume19
DOIs
StatePublished - Dec 28 2018

Keywords

  • CCLE
  • Cost optimization
  • Drug sensitivity prediction
  • GDSC
  • Latent variable
  • Nonlinear mapping
  • Pharmacogenomic studies
  • Transfer learning

Fingerprint

Dive into the research topics of 'Application of transfer learning for cancer drug sensitivity prediction'. Together they form a unique fingerprint.

Cite this